{"nctId":"NCT00227370","briefTitle":"Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation","startDateStruct":{"date":"2003-07"},"conditions":["Cytomegalovirus Infections"],"count":136,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: valganciclovir"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"valganciclovir","otherNames":["valcyte"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria for Phase I:\n\n* Adult lung transplant recipients age 18 or older\n* At risk for CMV (donor or recipient serology must be positive for CMV)\n* Adequate hematological and renal function,\n* On intravenous (IV) ganciclovir within 24 hours of surgery\n* Agreement to use effective methods of contraception\n* Negative pregnancy\n* Tolerate oral medications within 2 weeks of transplant\n* Negative baseline CMV PCR\n* Able to understand and sign the informed consent\n\nExclusion Criteria for Phase 1:\n\n* Repeat transplantation\n* Mechanical ventilation at study entry\n* Oral or intravenous ganciclovir treatment outside the study protocol\n* Invasive fungal infection\n* Participation in another investigational study\n* Acute CMV infection or disease\n* Anti-CMV therapy within 30 days before enrollment\n* Uncontrolled diarrhea or malabsorption\n* Allergic reaction to study drug\n* Required use of prohibited medications\n* Lactating women\n* Pregnancy\n* Renal failure\n\nInclusion Criteria for Phase II:\n\n* Negative serial post transplant PCRs at day 75\n* Negative bronchial cultures for CMV\n* Adequate hematological and renal function at day 75\n* IV ganciclovir for up to 2 weeks post operation and open label up to day 90\n* Effective contraceptives\n* Negative pregnancy\n\nExclusion Criteria Phase II:\n\n* Renal failure\n* Serious adverse events (SAE) related to study drug\n* CMV disease (study endpoint)\n* Withdraw consent for Phase II","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of CMV End Organ Disease","description":"The primary study end point was CMV end-organ disease determined by positive tissue immunostain or characteristic histopathology assessed for within 300 days post randomization.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of CMV Syndrome","description":"CMV clinical syndrome, with either positive serum PCR or positive culture for CMV from bronchoalveolar lavage and at least 2 of the following: fever, leukopenia, thrombocytopenia, elevated liver function test results malaise, reduction in pulmonary function (FEV1) greater than 20percent of baseline, or radiographic infiltrate consistent with CMV (all in the absence of other causes)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Any CMV Infection","description":"Inclusive of CMV syndrome, disease, or infection not meeting primary end point.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Biopsy Proven Acute Lung Rejection","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Non-CMV Infection","description":"non cmv opportunistic infections","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Severity of Viremia","description":"upon diagnosis of cmv disease, the number of CMV DNA copies/mL as measured by PCR","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110,000","spread":null},{"groupId":"OG001","value":"3,200","spread":null}]}]}]},{"type":"SECONDARY","title":"Ganciclovir Resistance","description":"UL97 genotyping was done on all positive samples for CMV DNA at 1000 copies/mL, with resistance defined by the presence of 1 or more mutations shown by marker transfer to confer phenotypic ganciclovir resistance","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":35,"n":66},"commonTop":["RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS","GASTROINTESTINAL DISORDERS","LUNG TRANSPLANT REJECTION","OEDEMA PERIPHERAL","FATIGUE"]}}}